Retrospective Study
Copyright ©The Author(s) 2024.
World J Gastroenterol. Feb 28, 2024; 30(8): 863-880
Published online Feb 28, 2024. doi: 10.3748/wjg.v30.i8.863
Figure 1
Figure 1 Example of a computed tomography image used for skeletal muscle measurements.
Figure 2
Figure 2 Survival curves for (A) progression-free survival and (B) overall survival in the presence or absence of sarcopenia. PFS: Progression-free survival; OS: Overall survival.
Figure 3
Figure 3 Survival curves for (A) progression-free survival and (B) overall survival in the presence or absence of myosteatosis. PFS: Progression-free survival; OS: Overall survival.
Figure 4
Figure 4 Survival curves for (A) progression-free survival and (B) overall survival in participants with gastric cancer in the presence or absence of sarcopenia. PFS: Progression-free survival; OS: Overall survival.
Figure 5
Figure 5 Survival curves for (A) progression-free survival and (B) overall survival in participants with advanced gastric cancer in the presence or absence of myosteatosis. PFS: Progression-free survival; OS: Overall survival.
Figure 6
Figure 6 Nomogram for progression-free survival. A: Nomogram for progression-free survival (PFS); B: One-year and 3-year area under the curves for PFS; C: Calibration curves for PFS; D: Decision curve analysis for PFS. AUC: Area under the curve; PFS: Progression-free survival; OS: Overall survival; ALP: Alkaline phosphatase; Eosi: Eosinophil count; CA724: Carbohydrate antigen 724; CA125: Carbohydrate antigen 125.
Figure 7
Figure 7 Nomogram for overall survival. A: Nomogram for overall survival (OS); B: One-year and 3-year area under the curves for OS; C: Calibration curves for OS; D: Decision curve analysis for OS. AUC: Area under the curve; OS: Overall survival; TP: Total protein; Eosi: Eosinophil count; CA724: Carbohydrate antigen 724; CA125: Carbohydrate antigen 125.